New pill aims to slow lung scarring in IPF patients
NCT ID NCT06764862
First seen Apr 18, 2026 · Last updated May 14, 2026 · Updated 3 times
Summary
This study tested a new tablet called HSK44459 in 186 adults aged 40 and older with idiopathic pulmonary fibrosis (IPF), a disease that scars the lungs and makes breathing hard. The goal was to see if the drug could improve lung function over 12 weeks compared to a placebo. Researchers measured changes in forced vital capacity (FVC), a key breathing test, and checked for side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IDIOPATHIC PULMONARY FIBROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Peking Union Medical College Hospital
Beijing, Beijing Municipality, 100000, China
Conditions
Explore the condition pages connected to this study.